


AZD0022

Chemical Properties

CAS No. : 2958627-18-2
 Formula: C34H30F4N6O
 Molecular Weight: 614.64
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	AZD0022 is a selective, reversible, and orally active KRAS G12D inhibitor exhibiting high affinity for both active (KRAS G12D-GTP) and inactive (KRAS G12D-GDP) proteins, whilst demonstrating selectivity for wild-type KRAS. AZD0022 exhibits tumour marker inhibition in PDAC and NSCLC models, making it suitable for investigating tumours such as advanced solid tumours, pancreatic cancer, and colorectal cancer.
Targets(IC50)	Ras
In vitro	PKPD modelling of AZD0022 suggested an unbound IC50 of 1.4 nM for pRSK inhibition [1].
In vivo	In nude mice bearing GP2D human tumor xenografts, oral dosing of AZD0022 at 150mg/kg led to sustained plasma and tumor exposure, with tumor concentrations approximately 18-fold higher than plasma. Seven days of BID dosing at 150mg/kg resulted in up to 75% inhibition of pRSK, with dose-dependent target modulation observed across 10, 50, and 150mg/kg[1].

Solubility Information

Solubility	DMSO: 80 mg/mL (130.16 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (5.37 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.627 mL	8.1348 mL	16.2697 mL
5 mM	0.3254 mL	1.627 mL	3.2539 mL
10 mM	0.1627 mL	0.8135 mL	1.627 mL
50 mM	0.0325 mL	0.1627 mL	0.3254 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kevin Beaumont, et al. Abstract 841: The preclinical pharmacokinetics and pharmacodynamics of AZD0022: A potent, oral KRASG12D-selective agent exhibiting oral bioavailability and KRAS pathway suppression in the GP2D xenograft model. Cancer Res (2025) 85 (8_Supplement_1): 841.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481